Halozyme Therapeutics (HALO) Misses Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $106.33 -0.68%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
VIVE, ENSV, MDLM, More
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
VIVE, ENSV, MDLM, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $24.01 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
- Best Buy (BBY) Tops Q2 EPS by 12c, Offers Guidance
- Lucky Strike Entertainment Corporation (LUCK) reported Q2 Revenue ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
